However, the worth for Azer-Cel, like CF33, is whether it can expand to other liquid cancers so IMU isn't "well overvalued" for their 5 assets. The patient for DLBCL might be small but the treatment cost for rare cancer is very expensive, IMU has mentioned this in comparison to the cost for Auto CAR-T. Their strategy with CF33 and Azer-Cel is to target an unmet market for those who have failed multiple treatments which will allow them to gain Fast Track designation and quicker path to commercialisation, making it very attractive IP for BP and then BP with their resource can advance the IP to first line of treatment much quicker.
IMU Price at posting:
3.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)